What Elite Pharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 2 | 2 |
| Sells | 0 | 0 |
| Total trades | 2 | 3 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 130,000 | 130,000 |
| Disposed | 0 | 0 |
| Net activity | +130,000 | +130,000 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Dash Barry H | Director | Oct 09 | Open-market buy · P | +100,000 | $0.26 | +$26K | 3,365,555 |
| Dash Barry H | Director | Aug 19 | Open-market buy · P | +30,000 | $0.29 | +$8.61K | 3,265,555 |
| Plassche Douglas | EVP Operations | Jan 09 | Exercise / conversion · M | +2,500,000 | $0.03 | +$75K | 6,000,000 |
| Plassche Douglas | EVP Operations | Oct 02 | Open-market sale · S | −800,000 | $0.62 | −$499K | 3,500,000 |
| Elite Pharmaceuticals Inc /NV/ | EVP Operations | Aug 25 | Exercise / conversion · M | +2,500,000 | $0.03 | +$75K | 4,300,000 |
| Elite Pharmaceuticals Inc /NV/ | EVP Operations | Aug 22 | Open-market sale · S | −500,000 | $0.52 | −$262K | 1,800,000 |
| Kirkov Kirko | Chief Commercial Officer | Jul 10 | Open-market buy · P | +16,366 | $0.59 | +$9.64K | 16,366 |
| Plassche Douglas | EVP Operations | Jul 08 | Open-market sale · S | −200,000 | $0.58 | −$116K | 2,300,000 |
| Plassche Douglas | EVP Operations | Jul 03 | Exercise / conversion · M | +2,500,000 | $0.03 | +$75K | 2,500,000 |
| Plassche Douglas | SVP of Operations | Oct 24 | Open-market sale · S | −333,932 | $0.51 | −$170K | 0 |
| Plassche Douglas | SVP of Operations | Oct 23 | Open-market sale · S | −800,000 | $0.49 | −$392K | 333,932 |
| Hakim Nasrat A | CEO, President | Mar 29 | Grant / award · A | +49,534,368 | — | — | 216,649,250 |
| Dash Barry H | Director | Nov 22 | Grant / award · A | +547,657 | $0.04 | +$20K | 3,235,555 |
| Caskey Davis S | Director | Nov 22 | Grant / award · A | +547,657 | $0.04 | +$20K | 2,049,436 |
| Whitnell Jeffrey A | Director | Nov 22 | Grant / award · A | +547,657 | $0.04 | +$20K | 3,187,020 |
| Dash Barry H | Director | Aug 28 | Grant / award · A | +459,536 | $0.04 | +$20K | 2,687,898 |
| Caskey Davis S | Director | Aug 28 | Grant / award · A | +459,536 | $0.04 | +$20K | 1,501,779 |
| Whitnell Jeffrey A | Director | Aug 28 | Grant / award · A | +459,536 | $0.04 | +$20K | 2,639,363 |
| Dash Barry H | Director | Jun 30 | Grant / award · A | +295,570 | $0.07 | +$20K | 2,228,182 |
| Caskey Davis S | Director | Jun 30 | Grant / award · A | +295,570 | $0.07 | +$20K | 1,042,243 |
Loading...
